GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK stock fell early Wednesday on light sales of two key vaccines, Shingrix and Arexvy, though the company otherwise beat expectations.

GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss

GSK (GSK) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.97 per share a year ago.

GSK (GSK) Tops Q2 Earnings and Revenue Estimates

GSK shares fell Wednesday as investors concerns' about lawsuits surrounding the pharmaceutical giant's discontinued heartburn drug Zantac outweighed any positive impacts from its better-than-expected second-quarter results which saw it lift its full-year outlook.

GSK's better-than-expected results overshadowed by Zantac litigation

GSK PLC (LSE:GSK, NYSE:GSK) has raised its annual earnings and sales forecasts after a strong second-quarter performance driven by cancer and HIV treatments. However, the performance singularly failed to impress the market still worried about the potential financial whack the drug giant might take from ongoing Zantac litigation as the shares opened 1.3% lower.

GSK forecast upgrade fails to impress the market

British drugmaker GSK raised its annual earnings and sales forecasts on Wednesday and posted second-quarter results that beat market expectations, boosted by its cancer and HIV portfolio.

GSK raises annual profit and sales forecast after second quarter beat

Biogen

Moderna

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

GSK PLC (LSE:GSK, NYSE:GSK) said it has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court, which is part of the drug giant's long-running Zantac litigation. The UK pharma giant stressed it did not admit any liability in this settlement.

GSK reaches confidential settlement in Illinois

GSK PLC's (LSE:GSK, NYSE:GSK) respiratory syncytial virus vaccine, Arexvy, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use to extend its use to adults aged 50-59 who are at increased risk of RSV. If approved, it will be the first RSV vaccine for this age group in the EU.

GSK's vaccine receives positive European Medicines Agency opinion

British drugmaker GSK on Monday said it has agreed to confidentially settle a lawsuit in Illinois alleging its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation.

GSK settles another Illinois Zantac lawsuit

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why GSK (GSK) is a Strong Momentum Stock

The European Union health regulator on Friday recommended expanded use of GSK's respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59.

EU regulator recommends use of GSK's RSV shot in adults aged 50 to 59

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.

GSK Stock Before Q2 Earnings: To Buy or Not to Buy?

Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Earnings Expected to Grow: Should You Buy?

GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.

GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review

GSK stock has a long track record of lagging behind the broader markets. Under CEO Emma Walmsley, the drugmaker has made significant strides toward improving its core-value proposition to shareholders.

Is GSK a Top-Value Stock Right Now?

GRAIL Inc

ImmunityBio

Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year.

3 Top Cancer Treatment Stocks to Buy Now

Novo Nordisk

Novartis

Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless of the ongoing economic conditions.

The 3 Most Undervalued Pharma Stocks to Buy in July 2024

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). In February 2024, the World Health Organization (WHO) recommended the removal of B/Yamagata strains from seasonal influenza vaccines.1 The WHO recommends that egg-base.

GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK plc GSK boasts a diversified base and presence in different geographical areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug development.

Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?

UBS analysts have downgraded GSK PLC (LSE:GSK, NYSE:GSK) from a Buy to Neutral rating, citing uncertainties surrounding its vaccine portfolio and ongoing legal issues with Zantac. The decision comes as UBS revises its price target down to 1,580p, a significant reduction from the prior 2,040p estimate, reflecting a cautious outlook on future earnings.

GSK downgraded by UBS over vaccine concerns, Zantac litigation

GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over this period.

Will GSK Stock Rebound To Its 2022 Highs Of $47?

GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.

GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac

Drug maker GSK (GSK) agreed to pay up to $1.56 billion for the rights to develop, manufacture, and market COVID-19 and influenza vaccines being worked on in collaboration with German biotechnology company CureVac (CVAC).

GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines

CureVac B.V

The deal represents a vote of confidence in the future of the mRNA-based vaccine market.

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

British Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech soaring during premarket trading and strengthening the British drugmaker's vaccine portfolio as it tries to compete with the likes of Moderna, Pfizer and BioNTech.

News for GlaxoSmithKline Stock (GSK)